scholarly article | Q13442814 |
P356 | DOI | 10.1081/JA-200042287 |
P8608 | Fatcat ID | release_uz7aekec4fduho6tii3zuzyvve |
P698 | PubMed publication ID | 16040375 |
P5875 | ResearchGate publication ID | 7705886 |
P50 | author | Julio Montaner | Q1712378 |
Anita Palepu | Q42399208 | ||
Thomas Kerr | Q85344273 | ||
Evan Wood | Q85344858 | ||
Robert S Hogg | Q37837778 | ||
Martin T. Schechter | Q40448698 | ||
David C. Marsh | Q42393440 | ||
P2093 | author name string | Kathy Li | |
P2860 | cites work | Intensive injection cocaine use as the primary risk factor in the Vancouver HIV-1 epidemic | Q42595766 |
The potential public health and community impacts of safer injecting facilities: evidence from a cohort of injection drug users | Q42692167 | ||
Factors associated with persistent high-risk syringe sharing in the presence of an established needle exchange programme | Q43937466 | ||
Opportunities for prevention: hepatitis C prevalence and incidence in a cohort of young injection drug users | Q44116660 | ||
Audio-computer interviewing to measure risk behaviour for HIV among injecting drug users: a quasi-randomised trial | Q44460929 | ||
Prevalence and correlates of untreated human immunodeficiency virus type 1 infection among persons who have died in the era of modern antiretroviral therapy | Q45710860 | ||
Drug treatment on demand--not. | Q45993928 | ||
Cost-benefit and cost-effectiveness analysis of drug abuse treatment services. | Q51991546 | ||
The role of epidemiology in needle exchange programs. | Q52925559 | ||
Science and health policy: can they cohabit or should they divorce? | Q53513004 | ||
Needle exchange, pragmatism, and moralism. | Q53513008 | ||
Epidemiology and the politics of needle exchange. | Q53513014 | ||
Needle exchange and difficulty with needle access during an ongoing HIV epidemic | Q57259768 | ||
Rationale for evaluating North America's first medically supervised safer-injecting facility | Q57671841 | ||
HIV incidence among injecting drug users in New York City syringe-exchange programmes | Q30233828 | ||
Sex differences in risk factors for hiv seroconversion among injection drug users: a 10-year perspective | Q30670433 | ||
Do needle exchange programmes increase the spread of HIV among injection drug users?: an investigation of the Vancouver outbreak. | Q30730194 | ||
A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence | Q33923812 | ||
Feasibility, safety, and efficacy of injectable heroin prescription for refractory opioid addicts: a follow-up study | Q34101461 | ||
Needle exchange is not enough: lessons from the Vancouver injecting drug use study | Q34432600 | ||
The social determinants of emergency department and hospital use by injection drug users in Canada | Q36274713 | ||
Social costs of untreated opioid dependence | Q36274931 | ||
Risk-taking behaviors among injecting drug users who obtain syringes from pharmacies, fixed sites, and mobile van needle exchanges | Q36275042 | ||
Methadone maintenance vs 180-day psychosocially enriched detoxification for treatment of opioid dependence: a randomized controlled trial | Q41724594 | ||
P433 | issue | 8 | |
P921 | main subject | sociodemography | Q3487479 |
P304 | page(s) | 1153-1167 | |
P577 | publication date | 2005-01-01 | |
P1433 | published in | Substance Use and Misuse | Q15753729 |
P1476 | title | Sociodemographic disparities in access to addiction treatment among a cohort of Vancouver injection drug users. | |
P478 | volume | 40 |
Q42695632 | 'Because I've been extremely careful': HIV seroconversion, responsibility, citizenship and the neo-liberal drug-using subject |
Q39947017 | A peer-led mobile outreach program and increased utilization of detoxification and residential drug treatment among female sex workers who use drugs in a Canadian setting |
Q39858715 | A primary care/multidisciplinary harm reduction clinic including opiate bridging |
Q37154026 | Access to drug and alcohol treatment among a cohort of street-involved youth. |
Q35966106 | An Engineered Endomorphin-2 Gene for Morphine Withdrawal Syndrome |
Q36928874 | Can the chronic administration of the combination of buprenorphine and naloxone block dopaminergic activity causing anti-reward and relapse potential? |
Q59238934 | Complex vulnerabilities as barriers to treatment for illicit drug users with high prevalence mental health co-morbidities |
Q36616450 | Factors associated with inability to access addiction treatment among people who inject drugs in Vancouver, Canada |
Q36316034 | Factors that help injecting drug users to access and benefit from services: A qualitative study |
Q39959718 | Harm reduction in hospitals: is it time? |
Q35679629 | Inability to access addiction treatment among street-involved youth in a Canadian setting |
Q35127554 | Inability to access addiction treatment and risk of HIV infection among injection drug users recruited from a supervised injection facility. |
Q41502073 | Injection drug use cessation and use of North America's first medically supervised safer injecting facility |
Q34023279 | Methadone use among HIV-positive injection drug users in a Canadian setting |
Q37091192 | NAOMI: The trials and tribulations of implementing a heroin assisted treatment study in North America. |
Q47625227 | Need for equity in treatment of substance use among Indigenous people in Canada |
Q48013189 | Perceived unmet need and barriers to care amongst street-involved people who use illicit drugs. |
Q24673390 | Summary of findings from the evaluation of a pilot medically supervised safer injecting facility |
Q36985312 | The North American Opiate Medication Initiative (NAOMI): profile of participants in North America's first trial of heroin-assisted treatment. |
Q33874564 | The impact of engagement in street-based income generation activities on stimulant drug use cessation among people who inject drugs |
Q34764625 | The role of safer injection facilities in the response to HIV/AIDS among injection drug users. |
Q37329865 | Withdrawal from Buprenorphine/Naloxone and Maintenance with a Natural Dopaminergic Agonist: A Cautionary Note |